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gemcitabine was introduced in may 2009. After 6 cycles, the tumor 
was reduced on CT-scan. Blood pressure was low (100/60mmHg) 
leading to irbesartan interuption with normal bood pressure 
(120/70mmHg) afterwards. Maintenance chemotherapy was 
sustained with gemcitabine.
In february 2011, blood pressure increased again and patient 
reported left hip pain. CT scan showed an aggravation of the osteolysis. 
Gemcitabine and irbesartan were restarted. After 6 additional cycles 
of taxotere-gemcitabine, CT scann showed partial response, blood 
pressure was low and therapeutics (taxotere-gemcitabine and 
irbesartan) could be again interupted.
In november 2011, the patient was hospitalized in emergency 
for high blood pressure and hip pain. He benefited of analgesic 
radiotherapy and treatment by irbesartan 300mg per day.
In february 2012, chemotherapy with 4 cycles of taxotere-
gemcitabine was restarted and the daily dose of irbesartan can be 
decreased to 150mg. However, response was only partial and another 
chemotherapy by 3 cycles of doxorubicine-dacarbazine failed to 
improve osteolysis. Finally, another chemotherapy by yondelis 
induced stability of bone lesions on CT-scann and irbesartan dose 
can be again reduced. 
Discussion
This case is the first described of paraneoplasic hypertension 
revealing testicular tumor. This case is of particular interest since 
evolution over 3 years, shows a perfect correlation between blood 
pressure and leiomyosarcoma evolutivity. Moreover, since the patient 
understood this link, blood pressure automeasure were able to help 
detecting early tumor relapses.
Case Report
Mr F.P., a 33-y/o man consulted after 3 months of general status 
alteration with a loss of 7 kgs and nocturnal sweats. His blood pressure 
was controlled up to 190/110 mmHg. Clinical examination by general 
pratictioner was considered as normal. Bitherapy by calcium channel 
blockers and alpha blockers was given.
Few days later, hypertension was still severe between 160/100 
and 200/120mmHg despite the bitherapy. Blood analysis revealed 
potassium at 3,1mmol/L. The patient was then hospitalized in a 
nephrological department. Plasma renin activity and aldosterone 
were elevated as shown on (Table 1). Clinical examination revealed a 
8 cm mass in the left testicul, painless, of tissular consistency, without 
any inflammatory sign or adenopathy. Mr FP has noticed this mass 
for one year but this was rapidly growing within the last 2 months. 
Ultrasound and CT scan showed that the mass was depended on 
the left spermatic cord and associated with one nodule on liver, two 
juxta-hepatic, an osteolysis on the right hip and a mediastinal lymph 
node mass. The biopsy of the liver nodule revealed a leiomyosarcoma 
with high malignity staging.
Figure 1 shows the clinical evolution under therapeutics. An 
angiotensin receptor blocker (irbesartan 300mg per day) was 
introduced in april 2009 in place of bitherapy and succeeded 
to normalize both blood pressure and kaliemia (respectively 
130/80mmHg and 4,5mmol/L). A chemotherapy by taxotere-
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Patient Norm
Potassium (mmol/L) 3,1 3,5-5,0
Aldosterone (pg/mL)
−	 lying
−	 standing
413
1925
10-100
30-270
Renin activity (pg/mL)
−	 lying
−	 standing
> 320
> 320
10-48
14-71
Table 1: Biochemical parameters.
Figure 1: Evolution of daily dose of irbesartan and chemotherapies (docetaxel 
gemcitabine high dose for intensive treatment and gemcitabine low dose for 
maintenance therapy). 
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Mr FP presented with secondary hypertension, with 
hyperreninism which can be due to paraneoplasic syndrom or renin 
secretion by the tumor. Because of metastasis, orchidectomy was not 
indicated and no primary tumor histology could be realized. Liver 
metastasis biopsy did not show any staining for renin but we cannot 
eliminate a primary renin tumor in testicule.
Renin secreting tumors are rare. The most frequent histological 
type is renal juxta-glomerular apparatus tumor [4]. However, uterin 
leiomyosarcoma has already been described in a 60 y/o woman with 
hypertension and hypokaliemia [1]. Immunocytochimy revealed 
renin expression. Blood pressure got normal after tumor removal. 
Hyperreninism has also been described with ovarian Sertoli cell tumor 
[2] and neuroendocrine pancreatic carcinoma [3]. Finally, this case 
underlines the importance of a complete examination and a biological 
assessment in front of unusual hypertension, especially if hypertension 
is resistant and/or on a young patient. Role of hormones on vascular 
tone and blood pressure should never be negliged as well showed on 
postmenopausal women treated with estrogeno therapy [5,6].
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